PRO (Patient Reported Outcome) information is collected directly from the patient via a questionnaire. Essential is the patient’s consent to the collection and use of this information. This information is essential for evaluating treatments and their impact on the quality of life of patients.
In various clinical studies, the evaluation of this information is mandatory. In routine treatment however, these patient responses are currently not recorded. Similar to the AMR, information from the routine treatment is clearly more significant than study data. They can be used directly for the detection of side effects, therapy optimization and the estimation of psychooncological needs.

Traditional outcome measures for the efficacy of oncological therapies are tumor response, disease-free and overall survival, time to disease progression, as well as the length of therapie-free time intervals. In oncology, however, modern medicine is not only concerned with combating tumor growth and prolonging life expectancy, but also with the alleviation of disease-related symptoms and limitations.

In any case, the diagnosis of cancer is associated with an elaborate treatment and aftercare. Therefore, the treatment focus must be based not only on the acute care but also on the long-term effects of oncological therapy such as, in particular, the maintenance or enhancement of the quality of life (Lipscomb, Reeve et al., 2007), their systematic and standardized recording can only be assessed by validated patient- Reported outcome (PRO) instruments. The large number of publications on the development and evaluation of cancer-specific PRO instruments from the 1990s onwards illustrates the increasing importance of PRO data in oncology (Garratt, Schmidt et al. 2002).

In addition, the electronic recording of PRO data also provides a time- and cost-efficient contribution to quality control. An optimized identification of “high-risk” and “high-use” patients is possible, which is otherwise only possible with increased personnel expenditure. Exactly these patient groups massively contribute to high costs in health care.

The structured, scientifically validated recording of patient data on symptoms and treatment sequences also contributes to treatment continuity and quality by helping to compensate for information gaps by routinely changing personnel.bild1

The Oncotyrol partner Evaluation Software Development (ESD), has developed a computer-based system that facilitates the acquisition and automated evaluation of PRO data.

Together with the TirolKliniken and ESD Oncotyrol implemented a routine assessment of PROs at the oncological outpatient clinic in Innsbruck.